SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
September 08 2021 - 4:05PM
Business Wire
SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA),
a leading provider of biopharmaceutical products in China, today
announced that CoronaVac®, an innovative, inactivated coronavirus
vaccine developed by SINOVAC Life Sciences Co., Ltd. (“SINOVAC”), a
subsidiary of the Company, received approval from the Public Health
Institute of Chile (“ISP”) for emergency use for children and
adolescents aged between 6 and 17.
ISP Director Heriberto Garcia made the announcement at a press
conference held following a meeting where experts discussed the use
of CoronaVac®. “Data shows the number of infected children has been
rising because they are not vaccinated. To continue protecting the
population, we have approved CoronaVac® for children aged six and
up," Garcia said. The ISP experts also highlighted the good safety
profile and tested immunogenic response of CoronaVac®.
CoronaVac® had been approved for emergency use in the population
aged from 3 to 17 years old on May 28, 2021, in China. It was also
approved for use in the population aged from 12 to 17 years old by
Indonesian authorities in June 2021.
The Lancet Infectious Diseases has published results from the
Phase I/II clinical trials of CoronaVac® in healthy children aged 3
to 17 years of age in China.
At this time, SINOVAC has provided CoronaVac® to nearly 50
countries and regions, including mainland China. The total supply
has already exceeded 1.8 billion doses. Moreover, it’s estimated
that over 1.4 billion doses have been administrated worldwide.
SINOVAC has become the largest domestic supplier and exporter of
China’s COVID-19 vaccine. The safety and effectiveness of
CoronaVac® has been verified around the world.
About SINOVAC
SINOVAC Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases. SINOVAC's product portfolio includes vaccines against
COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal
influenza, 23-Valent pneumococcal polysaccharide (“PPV”), H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu),
varicella, mumps and Poliomyelitis. SINOVAC’s COVID-19 vaccine,
CoronaVac®, has been granted emergency use approval or conditional
marketing authorization by over 50 countries or regions worldwide.
Healive®, the hepatitis A vaccine manufactured by the Company, has
passed the assessment under WHO prequalification procedures in
2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC
against hand foot and mouth disease caused by EV71, was
commercialized in China in 2016. In 2009, SINOVAC was the first
company worldwide to receive approval for its H1N1 influenza
vaccine, which it has supplied to the Chinese Government's
vaccination campaign and stockpiling program. The Company is also
the only supplier of the H5N1 pandemic influenza vaccine to the
government stockpiling program. In 2021, SINOVAC’s Sabin-strain
inactivated polio vaccine has approved for registration. The
Company is developing several new products including combined
vaccines. SINOVAC primarily sells its vaccines in China, while also
exploring growth opportunities in international markets. The
Company is seeking market authorization of its products in over 30
countries outside of China. For more information, please see the
Company’s website at www.sinovac.com.
Safe Harbor Statement
This press release may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as “will,” “expects,” “anticipates,” “future,”
“intends,” “plans,” “believes,” “estimates” and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements. In particular, the outcome
of any litigation is uncertain, and the Company cannot predict the
potential results of the litigation it filed or filed against it by
others. Additionally, the triggering of a shareholder rights plan
is nearly unprecedented, and the Company cannot predict the impact
on the Company or its stock price as a result of the trigger of the
rights plan.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005821/en/
Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871 or
+86-10-5693-1897 Fax: +86-10-6296-6910 Email: ir@sinovac.com ICR
Inc. Bill Zima U.S.: 1-646-308-1707 Email:
william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024